Media Highlights and Announcements

Fresh from its ASX debut, AYA’s mission is simple: it’s out to more accurately and less invasively detect signs of heart disease with the power of artificial intelligence (AI).

Learn More

Local medtech Artya has listed on the stock exchange, having earlier raised $40 million through an IPO to help commercialise its cardiac imaging software.

Learn More

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering (IPO).

Learn More

The medical technology company listed today after raising $40 million at $1.35. Its share price is up ~13% to $1.52.

Learn More

AI medical technology company Artrya Limited is announcing its partnership with leading global commercial services provider EVERSANA Life Sciences LLC.

Learn More

In this Stockhead article, Tim Boreham dives into Artrya as a company and shares his thoughts in the current $100M market valuation. He also speaks on Artya’s recent accomplishments as well as goals in the months and years to come.

Learn More

Artrya has been accepted onto the UK National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms.

Learn More

With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible.

Learn More

Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.

Learn More

Crawley-based Artrya has been shortlisted as a preferred supplier of AI Software by the UK Health Service for its heart disease detection program.

Learn More